FDA extends review time for Genta's appeal

Genta is going to have to wait a little longer before it gets final word on its appeal of the FDA's rejection of Genasense. The feds were supposed to act by the end of last year, but Genta says now that a decision won't be made until sometime in the current quarter. Genta had filed for approval to use Genasense with chemotherapy in patients with relapsed or refractory chronic lymphocytic leukemia.

- check out the release on the appeal

Suggested Articles

Across its 15-year history, Omega Funds has a hand in a clutch of high-profile biotechs such as Editas Medicine and Juno Therapeutics.

After Novartis’ near $10 billion buyout of The Medicines Company, many thought cardiovascular therapies were hot again.

Mutations in RIPK1 can cause uncontrolled cell death and inflammation, researchers discovered by studying families with an autoimmune disorder.